Details for Patent: 8,648,095
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,648,095 protect, and when does it expire?
Patent 8,648,095 protects REVLIMID and is included in one NDA.
This patent has three hundred and six patent family members in forty countries.
Summary for Patent: 8,648,095
Title: | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
Abstract: | Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. |
Inventor(s): | Zeldis; Jerome B. (Princeton, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 13/488,888 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,648,095 |
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 8,648,095
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE | See Plans and Pricing | |||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-001 | Dec 27, 2005 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE | See Plans and Pricing | |||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-002 | Dec 27, 2005 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE | See Plans and Pricing | |||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE | See Plans and Pricing | |||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE | See Plans and Pricing | |||
Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,648,095
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
African Regional IP Organization (ARIPO) | 2324 | See Plans and Pricing | |||
Argentina | 047994 | See Plans and Pricing | |||
Argentina | 057868 | See Plans and Pricing | |||
Argentina | 102756 | See Plans and Pricing | |||
Austria | 459357 | See Plans and Pricing | |||
Austria | 531369 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |